Crews Bank & Trust Buys New Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Crews Bank & Trust purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 212 shares of the pharmaceutical company’s stock, valued at approximately $85,000.

Other hedge funds have also recently made changes to their positions in the company. Lewis Asset Management LLC bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $302,000. Abel Hall LLC lifted its stake in Vertex Pharmaceuticals by 8.3% in the fourth quarter. Abel Hall LLC now owns 522 shares of the pharmaceutical company’s stock valued at $210,000 after buying an additional 40 shares during the period. Baader Bank Aktiengesellschaft lifted its stake in Vertex Pharmaceuticals by 1.6% in the fourth quarter. Baader Bank Aktiengesellschaft now owns 2,476 shares of the pharmaceutical company’s stock valued at $997,000 after buying an additional 38 shares during the period. Orrstown Financial Services Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 35.5% during the 4th quarter. Orrstown Financial Services Inc. now owns 947 shares of the pharmaceutical company’s stock worth $381,000 after buying an additional 248 shares in the last quarter. Finally, Strategic Blueprint LLC grew its position in shares of Vertex Pharmaceuticals by 35.5% during the 4th quarter. Strategic Blueprint LLC now owns 1,473 shares of the pharmaceutical company’s stock worth $593,000 after buying an additional 386 shares during the period. 90.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on VRTX. Truist Financial dropped their target price on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a research report on Monday, December 23rd. Jefferies Financial Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price objective for the stock from $500.00 to $550.00 in a research report on Monday, December 9th. Raymond James reaffirmed a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. Bank of America cut their price target on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a report on Thursday, December 19th. Finally, BMO Capital Markets decreased their price objective on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a report on Friday, December 20th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $502.58.

Vertex Pharmaceuticals Trading Up 5.3 %

NASDAQ:VRTX opened at $461.68 on Friday. The firm’s 50 day moving average is $434.34 and its 200 day moving average is $463.31. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same quarter last year, the business earned $3.67 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.